| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 50 | 17.8x | 17.8x | Around median | |
Growth | 58 | 2.5% | 7.1% | Around median | |
Quality | 88 | 17.7% | 4.5% | Top tier | |
Safety | 95 | — | 2.6x | Top tier | |
Capital Return | 94 | — | 2.12% | Top tier | |
Momentum | 62 | 72.4% | 2.9% | Around median | |
Sentiment | 42 | 12 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
United Therapeutics Corporation is a specialty pharmaceutical company whose commercial and development portfolio focuses on pulmonary and cardiopulmonary diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Revenue depends heavily on the Tyvaso franchise in its inhaled forms, while the company is working to expand its growth sources through ralinepag for pulmonary arterial hypertension, nebulized Tyvaso for idiopathic pulmonary fibrosis, and the treprostinil SMI device. It is also developing xenotransplantation programs including UKidney, UThymoKidney, and UHeart, and added a thymus-based regenerative medicine platform through the acquisition of Thymmune Therapeutics.
In Q2 FY2026, revenue reached $783.3 million, compared with $781.5 million in Q1 FY2026, representing limited sequential growth of approximately 0.2%. Gross profit was $683.8 million, with a gross margin of approximately 87.3%, and net income rose to $333.0 million from $274.9 million, while earnings per share increased to $7.27 from $5.82. Earnings per share exceeded market expectations, but revenue fell short of expectations, explaining the mixed nature of the results.
The Tyvaso franchise generated revenue of $453 million in Q2 FY2026, or approximately 57.8% of the company’s total revenue, making it the most important commercial driver in the reported mix. Nebulized Tyvaso faced competitive pressure, while Tyvaso DPI recorded all-time highs in treatment starts, referrals, total patients, and commercial patients exiting the quarter. On a trailing twelve-month basis, revenue was $3.2 billion, gross profit was $2.7 billion, and net income was $1.3 billion.
Analyst consensus rates UTHR shares a “Buy,” with an average price target of $643.75, within a wide range of $515 to $735. The average target is approximately 5.6% above the 52-week range high of $609.35, while the range low is $303.08, reflecting a very wide historical valuation range and meaningful variation among analyst estimates. The data does not include a usable price-to-earnings multiple, so the available valuation is based on the target range, the 52-week range, and the ability of the 2027 catalysts to offset slowing revenue and competition in Tyvaso.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
The Tyvaso franchise generated revenue of $453 million in Q2 FY2026, equivalent to approximately 57.8% of total revenue of $783.3 million. The franchise includes nebulized Tyvaso and Tyvaso DPI, which are used within the pulmonary and cardiopulmonary disease portfolio, with the DPI formulation recording all-time highs in treatment starts, referrals, and patient counts at the end of the quarter. The company is working to expand its revenue base through ralinepag in pulmonary arterial hypertension, nebulized Tyvaso in idiopathic pulmonary fibrosis, and treprostinil SMI.
Revenue reached $783.3 million and fell short of market expectations, while remaining nearly flat compared with revenue of $781.5 million in Q1 FY2026. In contrast, earnings per share exceeded expectations and reached $7.27, compared with $5.82 in the previous quarter. Net income rose to $333.0 million from $274.9 million, while gross profit reached $683.8 million with a margin of approximately 87.3%.
In late June 2026, the company submitted a supplemental application to FDA for nebulized Tyvaso in idiopathic pulmonary fibrosis following the TETON-1 and TETON-2 results. Management expects potential approval during 2027 and describes the opportunity as multibillion-dollar, but clarified that the initial launch in this indication would be limited to the nebulized formulation. The review takes six months if the application is granted priority and ten months under the standard pathway, and the review pathway had not been determined as of the August 7, 2026 call.
Automated analysis for informational purposes only — not investment advice.
United Therapeutics submitted a new drug application for ralinepag in pulmonary arterial hypertension following the ADVANCE OUTCOMES study results. Management describes it as the first once-daily oral prostacyclin and believes the clinical benefit data support a multibillion-dollar opportunity. The company is targeting potential approval during 2027 and also plans to submit an investigational new drug application for the ralinepag DPI formulation during 2026.
Management said on the August 7, 2026 call that it still sees a pathway to reaching a $4 billion annualized revenue run rate by the end of 2027, but acknowledged that this pathway has narrowed. Reaching the target may require contributions from the launches of nebulized Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension during 2027. The target’s sensitivity is increased because Q2 FY2026 revenue was $783.3 million and was nearly flat sequentially, and because the company did not reaffirm or update its FY2026 revenue growth guidance.
The company has three authorized clinical programs, including UKidney EXPAND, UThymoKidney EXTEND, and EXPRESS-UHeart. It expects to complete the initial cohort of six patients in UKidney EXPAND during 2026 and is working to initiate the registration-enabling UThymoKidney study and the UHeart study following FDA approval. It also plans to complete two additional commercial-scale production facilities in Minnesota and Texas by the end of 2026 and added a thymus-based platform through the acquisition of Thymmune Therapeutics.
